Kornimate/medical-research-clean huggingface dataset:
female sexual dysfunctions in chronic kidney disease

Conditions: Chronic Kidney Diseases

Summary: a myriad of sexual problems affect men and women with chronic kidney disease (ckd), including decreased libido, erectile dysfunction, dysmenorrhea, and infertility. menstrual abnormalities are common in ckd and many women are an-ovulatory. sexual dysfunction in ckd is multifactorial including hormonal alterations along with vascular, neurologic, psychogenic, and other factors, such as medications, contribute to the development of sexual dysfunction. sexual dysfunction in females is mainly due to hormonal factors and manifests mainly as menstrual irregularities, amenorrhea, lack of vaginal lubrication, and failure to conceive.

the study will be conducted on 100 female patients divided in to two equal group: 1. group a: the patient group include 50 female patients with chronic renal failure (egfr \<15ml/min/1.7m2 ) 2. group b: the control group including 50 healthy females age matched with the patient group. the female sexual function index (fsfi) will be used to assess sexual function. this index includes 19 questions related to 6 parameters: sexual desire, sexual arousal, lubrication, orgasm, sexual satisfaction and dyspareunia. a face-to-face inter-view with each participant in which the fsfi questions will be verbally asked and answered and compare between both groups in sexual activity and effect of chronic kidney disease on sexuality. duration of chronic kidney disease, duration of dialysis ,number of sessions of dialysis per week, medical treatment, haemoglobin,creatinine level will be fulfilled.

Eligibility criteria:
inclusion criteria: * female patients with chronic kidney disease stage 5 with estimated glomerular filtration rate (egfr) \<15 ml/min/1.7m2 using the equation of mdrd (modification of diet in renal disease) on dialysis or not. * age from 18 to 45 years old. * married. * sexually active during the last 6 months. exclusion criteria: * pregnant women. * other medical diseases (diabetes mellitus, coronary artery disease, neurological disorders and other systematic diseases). * taking medications affect sexuality function e.g. antidepressant drugs.
evaluate the efficacy and safety of rosuvastatin versus simvastatin in type 2 diabetic patients with dyslipidemia

Conditions: Diabetes Mellitus; Dyslipidemia

Summary: this is a phase iv, randomized, open-label, parallel-arm, comparative and forced- titration study to compare the efficacy and safety of rosuvastatin versus simvastatin in patients with type 2 dm and dyslipidemia. when comparing the efficacy of rosuvastatin 20 mg with simvastatin 40 mg for the treatment of type 2 dm with dyslipidemia, rosuvastatin 20 mg is superior to simvastatin 40 mg in achieving the combined goal of ldl-c (\<100 mg/dl) and non-hdl-c (\<130 mg/dl).

the duration of patient participation will be 18 weeks consisting of a 1-week screening period, a 5-week lead-in period, followed by a 12-week treatment period.

Eligibility criteria:
inclusion criteria: 1. male and female between the ages of 20-75 years. 2. female patients post menopausal, hysterectomized or if of childbearing potential using a reliable method of birth control. 3. diagnosed with type 2 diabetes mellitus. 4. fasting triglyceride ≧150 mg/dl ≦500 mg/dl or non-hdl-c≧130,but≦200 mg/dl 5. patients receiving stable antidiabetic treatment for 8 weeks before randomization (no change in the category of anti-diabetic agents, but the dose is adjustable). 6. all patients give written informed consent. exclusion criteria: 1. a history of hypersensitivity to statins. 2. a history of rhabdomyolysis or hereditary muscle disorders. 3. insulin-treated patients. 4. patient with any conditions of acute or chronic pancreatitis. 5. creatine kinase ≧3-fold upper limit of normal (uln). 6. patients with an estimated creatinine clearance (see note)≦30 ml/min or bilirubin ≧1.5-fold uln, or chronic active hepatitis or liver function impairment (ast and alt ≧3-fold uln). 7. overt proteinuria (repeat spot urine protein \>300mg/dl by dipstick method). 8. patients are taking cyclosporine. 9. a history of homozygous familial hypercholesterolemia or familial dysbetalipoproteinemia. 10. patients with alcohol and drug abuse in past 3 years. 11. serious or unstable medical or psychological conditions. 12. hypothyroidism (tsh \> 5 μiu/ml). 13. in the investigator's opinion, continuation in the study would be detrimental to the patient's well-being or might confound the clinical trial.
clinical investigation comparing two different ultra-porous coated surfaces of uncemented cups

Conditions: Osteoarthritis, Hip

Summary: a randomised controlled study comparing two types of ultra-porous coated uncemented cups in total hip arthroplasty. primary objective is to investigate if the clinical, radiological and patient-reported outcome of the new mobilelink tabeculink cup combined with an x-linked insert is non-inferior to the clinical and radiological outcome of the pinnacle gription series 100 cup combined with the marathon liner. patients are evaluated up to 15 years postoperatively.

the purpose of this study is to evaluate the clinical outcome and long-term risk of development of osteolysis of a newly introduced cementless press-fit acetabular cup, consisting of a shell with a 3d surface structure and a highly cross-linked liner by precise measurement of early migration and wear. migration describes the movement between the implant and the surrounding bone over time. early migration of the implant, within 2 years after operation, has shown to be a strong predictor for increased risk for late failure. thus, high precision migration studies can be used to evaluate the performance of new implants in small groups of patients with a relatively short observation time. wear particles are one of the main causes of periprosthetic osteolysis. although modern, more wear resistant materials, appears to have a greatly reduced risk of osteolysis, the desired complete elimination of osteolysis appears to be yet unachieved. it is most likely that the mechanism of periprosthetic osteolysis is multifactorial. in this study the investigators plan to include 70 patients that are planned for operation with an uncemented total hip arthroplasty. 35 patients will be randomized to receive the new implant and 35 patients will be included in the control group and receive a standard uncemented prosthesis. all patients will then be followed with ct scans and patient reported outcome measures 3-month, 1 year, 2 years, 5 years and 15 years after the operations. the ct scans will be used both for measurement of migration and wear and development of osteolysis around the implant.

Eligibility criteria:
inclusion criteria: * patients are foreseen for implantation of an uncemented acetabular press-fit cup and an uncemented stem * age 30-70 years * primary osteoarthritis of the hip * body mass index between 18 and 35 kg/m2 * willingness and ability to follow clinical investigation protocol exclusion criteria: * grossly abnormal hip anatomy (hip dysplasia, crowe grade 2 or above, perthes or other causes) * osteoporosis * paget's disease * inflammatory arthritis * secondary osteoarthritis * presence of malignancy in the area of surgery * treatment with bisphosphonates, cortisol or cytostatic drugs 6 months or less prior to surgery * previous surgery in the affected hip * inclusion of the contralateral hip in this clinical investigation * not suited for the clinical investigation for other reason (surgeon's judgment) * pregnant or breastfeeding women * prison inmate

Keywords: osteoarthritis total hip arthroplasty uncemented total hip arthroplasty
efficacy and safety study of las41007 in the treatment of actinic keratosis

Conditions: Actinic Keratosis

Summary: the aim of this study is to determine the efficacy, safety and tolerability of either a once or twice daily topical application of las41007 compared to a twice daily application of las106521 in the treatment of actinic keratosis.


Eligibility criteria:
inclusion criteria: * at least 4-10 clinically assessed actinic keratosis grade i to ii (according to olsen et al, 1991) in the face/forehead and/or on the bald scalp * the diameter of each ak target lesion is not less than 0.5 cm and not greater than 1.5 cm * the target lesions must be located in overall 2 treatment areas with a size of 25 cm2 per treatment area exclusion criteria: * have evidence of clinically significant or unstable medical conditions such as: * metastatic tumor or tumor with high probability of metastatic spread * heart failure (nyha class iii or higher) * immunosuppressive disorder (e.g. hiv) * hematologic, hepatic, renal, neurologic or endocrine disorder. * collagen-vascular disorder (e.g. cerebrovascular disorder or other bleedings). * gastrointestinal disorder (e.g. active ulcera or history of recurrent peptic ulcera or hemorrhage) * suffer from paresthesia in the treatment areas * show cornu cutaneum of the skin and/or hypertrophic ak lesions in the treatment areas

Keywords: actinic keratosis ak nmsc
efficacy of the sit to stand test in the decision to hospitalize a patient consulting the emergency dept for covid 19

Conditions: SARS-CoV Infection

Summary: as part of the coronavirus infectious disease 2019 (covid19) pandemic, the hospital care system is facing a major strain. patients with sars-cov2 (severe acute respiratory syndrome coronavirus 2 ) infection can worsen very quickly, possibly presenting, within hours, severe respiratory failure requiring urgent specialized care. therefore, it is essential to develop emergency assessment tools to assess relevant criteria to decide which patients must be kept under hospital monitoring and which patients can be treated on outpatient care. the aim of this study is to assess the efficacy of stst in the decision to hospitalize patients consulting emergency department for a sars-cov2 infection. the investigators wish to show that the addition of this test to the usual hospitalization criteria reduces the proportion of patients hospitalized 48 hours after their first visit to the emergency department.


Eligibility criteria:
inclusion criteria: * adult (≥18 years old) * admit to emergency department for suspected sars-cov2 infection * sars-cov2 infection confirmed by real time polymerase chain reaction (rt - pcr) before the first discharge of emergency department * patient affiliated or beneficiary of a health care insurance * effective contraception in women of childbearing age. for postmenopausal women, amenorrhea for at least 12 months before the inclusion visit exclusion criteria: * patient presenting criteria for admission to intensive care: signs of acute respiratory distress , respiratory rate\> 30 / min, oxygen dependence \> 6l / min on face mask for an spo2 ≥ 95% or an arterial oxygen pressure \>8kpa, neurological disorders, systolic blood pressure (sbp) \ 2mmol / l, bradycardia, or heart rate disorders * patient with spo2 \<90% in spontaneous ventilation in room air at rest * patient with functional impairment or deterioration of the general condition leading to the inability to perform stst * patient with a resting sbp\> 180 mmhg or resting diastolic blood pressure (dbp)\> 100 mmhg or resting heart rate (hr)\> 120 / min * patient with decompensated or unbalanced cardiac pathology * patient previously included in the study following a previous admission to emergency department * patient deprived of liberty, unable to consent freely * patient non affiliated or beneficiary of a health care insurance
utilizing social contacts to facilitate mammogram screening among african american women

Conditions: Breast Cancer

Summary: eliminating racial disparities in breast cancer is a top public health priority. african american (aa) women often present with more advanced and aggressive disease at the time of diagnosis and are more likely to die from breast cancer than any other racial/ethnic group in the united states. mammogram screening significantly reduces breast cancer mortality by diagnosing cancer at an earlier stage where treatments are more effective. while some aa women do not schedule screening mammograms as recommended by current guidelines, others do not show up for their exams after scheduling them (no-shows). no-shows to cancer screening appointments impose an enormous strain on our limited healthcare resources with negative impact on other patients who could have secured earlier appointments, loss of revenue for hospitals or clinics serving underserved populations and delays in diagnoses and treatment for those who do not have screening. the investigators identified a high no-show rate for screening mammograms at our hospital. aa women were almost three times more likely to no-show for their mammograms compared to white women. patient's social networks plan an important role in health promotion. in this study, we will pilot an intervention involving patient's social contacts (family, friends, neighbors, etc.) as healthcare facilitators to improve appointment attendance. the investigators seek to determine whether this intervention is feasible and acceptable to patients and whether this intervention will improve attendance rates for screening mammograms among aa women at our institution. if effective, the use of a patient's social contact person as a healthcare facilitator (similar to a patient navigator) would be a readily available and inexpensive resource for other institutions to implement.


Eligibility criteria:
inclusion criteria for patients: * female * african american * at least 40 years old * scheduled for a screening mammogram within 3 months following initiation of the study * willing and able to provide contact information for two adult social contacts (friends or family members) exclusion criteria for patients: -prior history of breast cancer inclusion criteria for social contacts: * at least 18 years old * selected by the patient as someone (family member or friend) who would be able to support her in keeping her mammogram appointment exclusion criteria for social contacts: -less than 18 years of age

Keywords: mammogram breast cancer screening african american women
sexuality and management of benign prostatic hyperplasia with alfuzosin

Conditions: Prostatic Hyperplasia

Summary: primary objective: * end-point improvement from baseline in male sexual health questionnaire ejaculation domain (mshq-ejd)in men with lower urinary tract symptoms (luts)suggestive of benign prostatic hyperplasia (bph) treated for 6 months with xatral 10mg once daily od. secondary objectives: * mshq-ejd improvement by visit * improvement in international prostate symptom score (ipss) total score, voiding and filling subscores, nocturia and bother score at end-point and by visit * onset of action of xatral 10mg od * tolerability of xatral 10mg od including occurrence of acute urinary retention.


Eligibility criteria:
inclusion criteria: * patients suffering from moderate to severe luts suggestive of bph * i-pss total score ≥ 8 * patients sexually active exclusion criteria: * known history of hepatic or severe renal insufficiency, unstable angina pectoris, concomitant life-threatening condition * previous prostate surgery, minimally invasive procedure within 6 months prior to inclusion. planned prostate biopsy, prostate surgery or minimally invasive procedure during the whole study period * active urinary tract infection or prostatitis, neuropathic bladder, a diagnosed prostate cancer * treatment with 5alpha-reductase inhibitors or phytotherapy within 6 months prior to inclusion, or alpha1-blockers within 30 days prior to inclusion * patients receiving any treatment for erectile dysfunction (i.e. phosphodiesterase-5 inhibitors) at inclusion * history of postural hypotension or syncope * known hypersensitivity to alfuzosin the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
modified tian wang bu xin dan hydrogel patch in preventing postoperative delirium in elderly patients

Conditions: Postoperative Delirium

Summary: the purpose of this study is to determine whether preoperative administration of modified tian wang bu xin dan hydrogel patch prevents the incidence of postoperative delirium in elderly patients undergoing major surgery.

the traditional chinese medicine (tcm) tian wang bu xin dan (twbxd, cheonwangbosimdan), first recorded in effective formulae handed down for generations ( shi yi de xiao fang) in 1337, is a herbal medicine that has been continuously utilized in chinese medicine. it alleviates insomnia, anxiety, and palpitation by furnishing energy and stabilizing patients' mind. cheonwangbosimdan can mitigate primary insomnia and secondary insomnia in patients with hyperthyroidism and menopause without severe side effects. tianwang buxin decoction has the same effect as olanzapine for the treatment of delirium after hip joint replacement in falling-induced senile femoral neck fracture patients. this study aim to evaluate the incidence of postoperative delirium in elderly patients treated with prophylactic modified cheonwangbosimdan hydrogel patch versus placebo patch.

Eligibility criteria:
inclusion criteria: 1. patients' age ≥70 years; 2. underwent elective non-cardiac surgery (including orthopedics, thoracic, urology, general surgery patients)under general anesthesia ; exclusion criteria: 1. history of neuropsychiatric diseases including delirium, mental disorders, parkinson, dementia, etc.; 2. the operation was cancelled due to various reasons after the patient was enrolled; 3. severe liver disease; severe renal dysfunction defined as either having creatinine clearance \< 30 ml/min or being dialysis-dependent; 4. patients who undergo second operation in a short period; 5. past 30-day prescribed use of sedative-hypnotics for the indication of insomnia; 6. history of alcohol abuse or a history of drug dependence; 7. cannot with the completion of tests of cognitive function; 8. known allergy to skin patch; 9. treatment site has active skin lesion or inflammation; 10. refused to participate in the study.
indomethacin for tocolysis of preterm labor

Conditions: Preterm Labor

Summary: indomethacin for tocolysis for 48 hours vs placebo

background: indomethacin is frequently used as a tocolytic, however there is currently only scant evidence to support its efficacy. goals: to delay preterm delivery by 48 hours and to examine longer latency periods and maternal and neonatal outcomes methods: randomized placebo-controlled trial of indomethacin for tocolysis. women with a singleton pregnancy between 23w0d and 31w6d in preterm labor randomly assigned to 50mg indomethacin by mouth followed by 25mg by mouth every 6hour for 48 hours or placebo. patients receive betamethasone for fetal lung maturity, if not previously administered, and magnesium sulfate for neuroprotection. ultrasound performed before initiation of study drug and after completion of study medication for amniotic fluid index and fetal cardiac assessment.

Eligibility criteria:
inclusion criteria: * preterm labor as defined by regular uterine contractions (at least 6/hour) with cervical change of at least 1 cm or cervical shortening on transvaginal ultrasound less than 25mm of functional length * gestational age 23w0d to 31w6d weeks * singleton * ≥ 18 years old * able to consent in english exclusion criteria: * major congenital anomalies associated with an increased risk of newborn death * multiple fetal gestation (2+) * known intrauterine fetal demise * non-reassuring fetal status requiring delivery * preterm premature rupture of membranes (pprom) * suspected or known intrauterine infection * placenta previa * maternal allergy or contraindication to indomethacin (peptic ulcer disease, thrombocytopenia, coagulopathy, renal or hepatic dysfunction) * inevitable delivery (cervix ≥6cm dilated)

Keywords: preterm labor tocolysis indomethacin
the nutrition care in canadian hospitals study; 2010-2013.

Conditions: Malnutrition

Summary: the nutrition care in canadian hospitals study, conducted by the canadian malnutrition task force had the primary purpose of determining the prevalence of malnutrition in canadian acute care hospitals. secondary objectives were to determine the independent association of malnutrition with patient centred outcomes (e.g. length of stay) and describe the nutrition care processes for malnourished and well nourished patients.

data from 18 community and academic hospitals was collected from a convenience sample of 1022 medical or surgical patients. this prospective cohort study followed patients throughout their admission to 30-day post discharge. measures included nutrition indicators, nutrition care processes and health outcomes.

Eligibility criteria:
inclusion criteria: * acute care admission, medical or surgical unit; english or french language;anticipated to stay in hospital for 2 or more days; consent to study entry; exclusion criteria: other hospital units; palliative patients; unable to complete informed consent due to language barrier or no proxy available; dementia -
prevalence of genetic mutations in patients with neuropathy associated with anti-myelin-associated glycoprotein (mag) antibodies

Conditions: Neuropathy Demyelinating

Summary: anti-mag (myelin associated glycoprotein) neuropathy is related to clonal b lymphocyte proliferation producing an monoclonal immunoglobulin (igm) with anti-mag activity. igm may be a reflection of malignant lymphoproliferative syndrome (waldenström disease) or, more often, monoclonal gammopathy of unknown significance. the anti-mag antibody has a direct toxicity on the myelin sheath of the peripheral nervous system responsible for a length-dependent demyelinating polyneuropathy. clinically, this results in a sensitive, ataxic predominant polyneuropathy in the lower limbs, sometimes associated with a tremor of attitude and action tremor of the upper limbs. clonal b cells at the origin of igm production may have acquired mutations affecting myd88 (myd88 l265p mutation) and cxcr4 (whim-like cxcr4 mutation). the prevalence of the myd88 l265p mutation is estimated to be 50% in monoclonal gammopathies of undetermined significance and more than 80% in waldenström disease. cxcr4 whim-like mutations are found in 40% of patients with waldenström's disease. no studies have reported the prevalence of these mutations in patients with anti-mag neuropathies.

this is a retrospective observational study in patients with anti-mag neuropathy. mutational analysis will be performed for patients with a medullary or blood sample stored in a bio-bank during lymphocyte phenotyping. this phenotyping was carried out most often in search of a malignant haemopathy associated with the monoclonal peak. no new samples were taken from the patient (blood or spinal cord). immunoglobulin gene rearrangement of the clonal b cells are also assessed.

Eligibility criteria:
inclusion criteria: * patients with anti-mag neuropathy * blood and/or bone marrow samples available in bio-bank * given informed consent exclusion criterion * participation refusal

Keywords: anti-mag neuropathy waldenström disease mutational analysis
effects of exercise training in bariatric patients

Conditions: Obesity

Summary: bariatric surgery may attenuate insulin resistance and low-grade inflammation in obese subjects. this trial aims to test whether exercise training can add to the benefits of bariatric surgery on insulin sensitivity and inflammation. in addition, this study aims to investigate whether exercise training can counteract bone loss induced by bariatric surgery.


Eligibility criteria:
inclusion criteria: * body mass index ≥ 35 kg/m2 * not engaged in physical activity programs * without any physical limitation that could preclude exercise participation exclusion criteria: * body mass index \< 35 kg/m2 * regular participation in physical activities programs * cancer or any other disease that could limit participation in exercise